Company Focus
LabCorp
Latest LabCorp News
Pharmaceutical
The US Federal Trade Commission has withdraw its appeal Laboratory Corporation of America's (NYSE: LH) 2010 $57.5 million acquisition of Westcliff Medical Laboratories (The Pharma Letter December 3, 2010). Although LabCorp consummated the acquisition in June 2010, the FTC was seeking the federal court injunction to prevent LabCorp from integrating the companies pending the outcome of administrative litigation. The FTC also has withdrawn the matter from administrative adjudication - a step that stops the trial proceedings, but does not conclude the case. 28 March 2011
Related News
Insights
Company Spotlight
A Canadian biotech company focussed on utilising lipid nanoparticle (LNP) for nucleic acid delivery.
Latest News & Features of interest to LabCorp
Biotechnology
Novartis has announced positive Phase III trial results for its investigational gene therapy, onasemnogene abeparvovec, in children and young adults with spinal muscular atrophy (SMA) Type 2. 30 December 2024
Biotechnology
French specialty vaccine company Valneva has entered into an exclusive license agreement for its single-shot chikungunya vaccine that enables supply of the vaccine in Asia with Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses. 24 December 2024
Pharmaceutical
French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience in pneumococcal vaccines, with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations. 23 December 2024
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Biotechnology
Astellas Pharma has struck a licensing agreement with Sangamo Therapeutics to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. 20 December 2024
Pharmaceutical
In significant efforts to strengthen public health and improve vaccine access in Africa, the US International Development Finance Corporation, the African Development Bank and the International Finance Corporation (IFC) have jointly announced a $45 million financing package for VaxSen, a subsidiary of Senegal’s Institut Pasteur de Dakar (IPD). 18 December 2024
Biotechnology
China's drug regulator has approved clinical trials for an experimental mpox vaccine developed by Sinopharm, marking a significant step in the country’s efforts to offer an alternative jab. 17 December 2024
Biotechnology
Danish vaccine maker Bavarian Nordic has signed a licensing and manufacturing agreement with the Serum Institute of India (SII) to expand production capacity for its mpox vaccine Jynneos. 17 December 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at its December 2024 meeting, bringing the total number of medicines recommended for approval in 2024 to 114. 13 December 2024
Pharmaceutical
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
Latest In Brief for LabCorp
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, GSK’s recombinant zoster vaccine for the prevention of shingles (herpes zoster). 10 January 2025
Latest Relevant Ones To Watch News
Belgian biotech Galapagos plans to divide into two distinct entities, separating its cell therapy operations from a new spin-off company. 8 January 2025
26 November 2024
19 November 2024
26 October 2024
24 October 2024
18 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze